Keenova Therapeutics announces impressive first-quarter 2026 financial results driven by strong sales of Acthar Gel and XIAFLEX.

Keenova Therapeutics has announced the publication of a new manuscript on Acthar Gel's use for treating severe autoimmune diseases in the Journal of Comparative Effectiveness Research, shedding light on real-world clinical data.

Keenova Therapeutics has announced an impressive performance in Q2 2026, driven by strong brand growth and strategic advancements in its pipeline.

Keenova Therapeutics showcases impressive Q4 results, driven by strong sales in Acthar Gel and XIAFLEX, as the company transitions successfully into a branded therapeutics entity.

Mallinckrodt reports impressive financial results for Q3 2025 with $753.1 million in sales, primarily driven by Acthar Gel and the recent merger with Endo. The company outlines future expectations.

Mallinckrodt plc reveals findings on the effectiveness of Acthar Gel in managing symptoms for patients with ankylosing spondylitis and psoriatic arthritis.

Mallinckrodt plc announces its financial results for the second quarter of 2025, marking a revenue dip but strong performance in key areas amidst a significant merger.

Discover the recent survey findings published by Mallinckrodt that highlight patient satisfaction with the Acthar® Gel SelfJect Injector, showcasing ease of use and confidence among users.

Mallinckrodt highlights real-world data on Acthar Gel for systemic lupus erythematosus at LUPUS 2025, showcasing treatment effectiveness and patient profiles.

Mallinckrodt plc has reported its Financial Results for the first quarter of 2025, showing key areas of growth and reaffirming its full-year guidance amidst ongoing challenges.